1B1

ONCOARENDI THERAP ZY-01

Healthcare · EUR · F

1B1

Price

€1.2

+0.00%

Cap

€24.72M

Earnings

30d Trend

-9.3%

1B1
Loading chart data...
0 days · % change from startPowered by Brain47
VolatilityHigh

64% annualised over 90 days

BRAIN47 SIGNAL

0
VERY WEAK
Risk Level71
Quality15
Momentum22
Technical37
Fundamentals15

Raw weighted: 24×Macro 0.99 (1%)=24

RISK

71/100
90d Volatility
64.2%High
ATR %
2.5%Normal
Max Drawdown (1Y)
-43.2%Volatile

QUALITY

15/100
ROE (avg)
-16.3%Negative
Piotroski F-Score
1/9Weak
Accruals
22.6%Accrual heavy

MOMENTUM

22/100
12-1M Momentum
-26.7%Strong downtrend
6-1M Momentum
-12.0%Negative
1M Return
-7.4%Recent pullback

TECHNICAL

37/100
RSI (14)
43.3Neutral
Price vs SMA200
-23.1%Bearish trend
MACD
-0.01Bearish momentum
Bollinger Band
19%Near lower band
SMA Cross
Golden CrossGolden Cross
Trend Quality (KER)
0.092Noisy/choppy

FUNDAMENTALS

15/100
P/S
1000000.0Expensive

Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months41
3-12 months23
1-5+ years18

Limited short-term thesis

BRAIN47'S ASSESSMENT

I rate ONCOARENDI THERAP ZY-01 at 24/100 — a VERY WEAK reading on the Brain47 Signal. The strongest factor is technical at 37/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.

PAST PERFORMANCE

1 MONTH

-7.4%

3 MONTHS

-32.4%

12 MONTHS

-34.1%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

Limited short-term thesis. Technical (37) and low-risk profile are the primary strengths. I note that fundamentals is the weakest area at 15/100 — this warrants monitoring. Historical volatility is elevated at 64%. I classify this as a speculative position — elevated volatility at 64% and smaller market cap define the opportunity.

speculativeScore: 24/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.